# US 11,896,753 B2 · Therapeutic compositions for viral-associated disease states and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,753 B2
- Document ID: US11896753B2
- Status: Granted
- Kind: B2
- Application number: 16/807,858
- Filed: 2020-03-03
- Published: 2020-06-25
- Granted: 2024-02-13
- Earliest claimed: 2014-09-25
- Assignees: Immutrix Therapeutics, Inc.
- Applicants: Immutrix Therapeutics, Inc.
- Inventors: Carol A. Rae; Jan Simoni; Grace Simoni; John F. Moeller
- Web page: https://patentgrep.com/patent/US11896753B2

## CPC

- A61M 1/3679: {by absorption (A61M1/3675 takes precedence)}
- A61M 1/0281: {Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing}
- A61M 1/14: Dialysis systems; Artificial kidneys; Blood oxygenators (semi-permeable membranes characterised by the material, manufacturing processes therefor B01D71/00){; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis}
- A61M 1/3687: {Chemical treatment (A61M1/3675 takes precedence)}
- B01J 20/20: comprising free carbon; comprising carbon obtained by carbonising processes
- B01J 47/02: Column or bed processes
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS

## Abstract

A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.

## Claims

### Claim 1

A method comprising:
contacting a bodily fluid with an adsorbent material consisting essentially of a synthetic carbon particle (SCP) to produce a first filtrate, wherein the bodily fluid comprises a level of disease mediators (y);
contacting the first filtrate with an adsorbent material consisting essentially of the SCP and an anion exchange resin where the weight ratio of SCP to anion exchange resin is in a range from 0.1:100 to 100:0.1 to produce a second filtrate;
contacting the second filtrate with an adsorbent material consisting essentially of the SCP and a cation exchange resin where the weight ratio of SCP to cation exchange resin is in a range from 0.1:100 to 100:0.1 to produce a third filtrate; and
administering the third filtrate to the subject.

### Claim 2 (depends on 1)

The method of claim 1 wherein the disease mediators are related to at least one virus associated with an immunosuppressive event.

### Claim 3 (depends on 2)

The method of claim 2 wherein the virus associated with the immunosuppressive event is a member of a viral family selected from the group consisting of Arenaviridae, Bunyaviridae, Filoviridae, Flaviviridae, Coronavirinae, Bunyaviridae, and Orthomyxoviridae.

### Claim 4 (depends on 2)

The method of claim 2 wherein the bodily fluid comprises Hantavirus, MERS-coronavirus (MERS-CoV), Influenza A virus subtype H5N1, Influenza A (H1N1) virus, Ebola Virus, Marburg virus, or combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1 further comprising sanitizing the SCP, the anion exchange resin, and the cation exchange resin prior to contacting with the bodily fluid.

### Claim 6 (depends on 1)

The method of claim 1 further comprising contacting the SCP, the anion exchange resin, and the cation exchange resin with a compatibilizer prior to contacting the SCP, the anion exchange resin, and the cation exchange resin with the bodily fluid.

### Claim 7 (depends on 6)

The method of claim 6 wherein the compatibilizer comprises a polysaccharide, a glucan, albumin, mannitol, a starch, or combinations thereof.

### Claim 8 (depends on 6)

The method of claim 6 wherein the compatibilizer comprises dextran.

### Claim 9 (depends on 8)

The method of claim 8 wherein the dextran has an average molecular weight of from 1 kDa to 500 kDa.

### Claim 10 (depends on 6)

The method of claim 6 wherein the compatibilizer comprises hydroxyethyl starch.

### Claim 11 (depends on 6)

The method of claim 6 wherein the compatibilizer comprises albumin and mannitol.

### Claim 12 (depends on 1)

The method of claim 1 wherein a level of a disease mediator in the third filtrate is reduced by 100% when compared to the level of disease mediators (y).

### Claim 13 (depends on 12)

The method of claim 12 wherein the disease mediators are selected from the group consisting of IL-18, IFN-γ, TNF-α, IL-1β, 1L-6, IL-10, MCP-1, MCSF, MIP-1 α, NO, C3a, C5a, histamine, and combinations thereof.

### Claim 14

An extracorporeal system comprising:
a first column, wherein the first column consists essentially of synthetic carbon particles (SCP):
a second column, wherein the second column consists essentially of a mixture of SCP and an anionic exchange resin; and
a third column, wherein the third column consists essentially of a mixture of SCP and a cationic exchange resin;
and
a computer system.

### Claim 15 (depends on 14)

The extracorporeal system of claim 14 wherein the SCP and the anion exchange resin are present in an amount of 1 wt. % SCP to 99 wt. % anion exchange resin.

### Claim 16 (depends on 14)

The extracorporeal system of claim 14 wherein the SCP and the cation exchange resin are present in a ratio of 1 wt. % SCP to 99 wt. % cation exchange resin.

### Claim 17 (depends on 14)

The extracorporeal system of claim 14 further comprising the SCP, the anion exchange resin, and/or the cation exchange resin having at least a portion of their surface coated with a compatibilizer.

### Claim 18 (depends on 17)

The extracorporeal system of claim 17 wherein the compatibilizer comprises a glucan.

### Claim 19 (depends on 17)

The extracorporeal system of claim 17 wherein the compatibilizer comprises dextran.

### Claim 20

An extracorporeal system comprising:
a first column, wherein the first column consists essentially of synthetic carbon particles:
a second column, wherein the second column consists essentially of a mixture of synthetic carbon particles and a first ion exchange resin; and
a third column, wherein the third column consists essentially of a mixture of synthetic carbon particles and a second ion exchange resin.